Tallahassee Journal

Advanced Non-squamous And Squamous NSCLC Pipeline Insight | Companies – Daiichi Sankyo Company, Genentech, Sinocelltechm, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others

 Breaking News
  • No posts were found

Advanced Non-squamous And Squamous NSCLC Pipeline Insight | Companies – Daiichi Sankyo Company, Genentech, Sinocelltechm, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others

May 25
15:55 2023
Advanced Non-squamous And Squamous NSCLC Pipeline Insight | Companies - Daiichi Sankyo Company, Genentech, Sinocelltechm, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others

DelveInsight’s, “Advanced Non-Squamous & Squamous NSCLC Pipeline Insight 2023” report provides comprehensive insights about 9+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape. It covers the Advanced Non-Squamous & Squamous NSCLC pipeline drug profiles, including Advanced Non-Squamous & Squamous NSCLC clinical trials and nonclinical stage products. It also covers the Advanced Non-Squamous & Squamous NSCLC therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

To explore more information on the latest breakthroughs in the Advanced Non-squamous and Squamous NSCLC Pipeline treatment landscape of the report, click here @ Advanced Non-squamous and Squamous NSCLC Pipeline Outlook

 

Key Takeaways from the Advanced Non-Squamous & Squamous NSCLC Pipeline Report

  • DelveInsight’s advanced Non-squamous and Squamous NSCLC Pipeline report depicts a robust space with 9+ active players working to develop 10+ pipeline therapies for Advanced Non-squamous and Squamous NSCLC.
  • The leading Advanced Non-squamous and Squamous NSCLC Companies include Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others.
  • Promising Advanced Non-squamous and Squamous NSCLC Pipeline Therapies include TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection, Pemetrexed, Cisplatin (or carboplatin), Tislelizumab,Cisplatin or Carboplatin, Pemetrexed, Bevacizumab-Pfizer, Paclitaxel, Carboplatin, Sintilimab, IBI305, Pemetrexed, FKB238 (bevacizumab), Avastin (bevacizumab), Gemcitabine, and others
  • In March, 2023, Libtayo® (cemiplimab), in conjunction with platinum-based chemotherapy, has been approved by the European Commission (EC) for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) and 1% PD-L1 expression, according to Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), which made the announcement today. This covers individuals with tumours that have spread or are locally progressed and who are not candidates for definitive chemoradiation but also do not exhibit EGFR, ALK, or ROS1 abnormalities.
  • In May, 2023, Data for 4 approved drugs and two pipeline candidates in more than 25 types of cancer will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago from June 2–6. Merck (NYSE: MRK), also known as MSD outside of the United States and Canada. Presentations will highlight fresh or updated research from Merck’s extensive range of anti-cancer drugs, including WELIREGTM (belzutifan), LYNPARZA® (olaparib), LENVIMA, and KEYTRUDA, an anti-PD-1 treatment developed in partnership with AstraZeneca. Merck will also present data from its extensive pipeline, including MK-2870/SKB264, an anti-TROP2 antibody-drug conjugate (ADC) being developed in partnership with Kelun-Biotech, and V940/mRNA-4157, an investigational personalised neoantigen therapy (INT) being developed in partnership with Moderna and used in conjunction with KEYTRUDA.

 

For further information, refer to the detailed Advanced Non-squamous and Squamous NSCLC Unmet Needs, Advanced Non-squamous and Squamous NSCLC Market Drivers, and Advanced Non-squamous and Squamous NSCLC Market Barriers, click here for Advanced Non-squamous and Squamous NSCLC Ongoing Clinical Trial Analysis

 

Advanced Non-squamous and Squamous NSCLC Overview

Lung cancer is one of the most common types of cancer across the globe and among the leading causes of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and is further classified into squamous NSCLC and non-squamous NSCLC (includes large cell histologies and adenocarcinoma). Squamous NSCLC accounts for about 30% of NSCLC cases while non-squamous NSCLC is more commonly observed. Squamous NSCLC is an aggressive form of lung cancer for which there is significant dearth of well-tolerated and effective treatments.

 

Request a sample and discover the recent advances in Advanced Non-squamous and Squamous NSCLC Ongoing Clinical Trial Analysis and Medications, click here @ Advanced Non-squamous and Squamous NSCLC Treatment Landscape

 

Advanced Non-Squamous & Squamous NSCLC Emerging Drugs

 

  • KN-046: Jiangsu Alphamab Biopharmaceuticals

KN-046 is a bispecific antibody targeting both programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The drug is in Phase III clinical studies for the treatment of Advanced Squamous Non-small Cell Lung Cancer.

 

  • Pyrotinib: Jiangsu HengRui Medicine

Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor developed for the treatment of HER2-positive advanced solid tumours. The drug is in Phase III clinical studies in patients with advanced non-squamous NSCLC harboring a HER2 exon 20 mutation who failed platinum based chemotherapy.

 

Dive deep into rich insights for drugs for Advanced Non-squamous and Squamous NSCLC Market Drivers and Advanced Non-squamous and Squamous NSCLC Market Barriers, click here @ Advanced Non-squamous and Squamous NSCLC Unmet Needs and Analyst Views

 

Advanced Non-squamous and Squamous NSCLC Pipeline Therapeutics Assessment

There are approx. 9+ key companies which are developing the therapies for Advanced Non-Squamous & Squamous NSCLC. The companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e. phase II include, Jiangsu Alphamab Biopharmaceuticals.

 

Scope of the Advanced Non-squamous and Squamous NSCLC Pipeline Report

  • Coverage- Global
  • Advanced Non-squamous and Squamous NSCLC Companies- Jiangsu Alphamab Biopharmaceuticals, Jiangsu HengRui Medicine, Daiichi Sankyo Company, Genentech, Sinocelltech, Merck KGaA, Mirati Therapeutics, Ability Pharmaceuticals, Axelar AB, and others.
  • Advanced Non-squamous and Squamous NSCLC Pipeline Therapies- TQB2450 injection, Tilelizumab injection, Anlotinib hydrochloride capsule, Pemetrexed disodium injection, Carboplatin injection, Pemetrexed, Cisplatin (or carboplatin), Tislelizumab,Cisplatin or Carboplatin, Pemetrexed, Bevacizumab-Pfizer, Paclitaxel, Carboplatin, Sintilimab, IBI305, Pemetrexed, FKB238 (bevacizumab), Avastin (bevacizumab), Gemcitabine, and others
  • Advanced Non-squamous and Squamous NSCLC Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Advanced Non-squamous and Squamous NSCLC Mergers and acquisitions, Advanced Non-squamous and Squamous NSCLC Licensing Activities @ Advanced Non-squamous and Squamous NSCLC Emerging Drugs, and Recent Trends

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Advanced Non-Squamous & Squamous NSCLC: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Advanced Non-Squamous & Squamous NSCLC – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. KN-046: Jiangsu Alphamab Biopharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Zuranolone: SAGE Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. ABTL0812: Ability Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Advanced Non-Squamous & Squamous NSCLC Key Companies
  21. Advanced Non-Squamous & Squamous NSCLC Key Products
  22. Advanced Non-Squamous & Squamous NSCLC- Unmet Needs
  23. Advanced Non-Squamous & Squamous NSCLC- Market Drivers and Barriers
  24. Advanced Non-Squamous & Squamous NSCLC- Future Perspectives and Conclusion
  25. Advanced Non-Squamous & Squamous NSCLC Analyst Views
  26. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services

Categories